Cargando…
Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054
BACKGROUND: Pathological and genetic evidence implicates toxic effects of aggregated α‐synuclein in the pathophysiology of neuronal dysfunction and degeneration in Parkinson's disease. Immunotherapy targeting aggregated α‐synuclein is a promising strategy for delaying disease progression. OBJEC...
Autores principales: | Brys, Miroslaw, Fanning, Laura, Hung, Serena, Ellenbogen, Aaron, Penner, Natalia, Yang, Minhua, Welch, Mackenzie, Koenig, Erica, David, Eric, Fox, Tara, Makh, Shavy, Aldred, Jason, Goodman, Ira, Pepinsky, Blake, Liu, YuTing, Graham, Danielle, Weihofen, Andreas, Cedarbaum, Jesse M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771554/ https://www.ncbi.nlm.nih.gov/pubmed/31211448 http://dx.doi.org/10.1002/mds.27738 |
Ejemplares similares
-
Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain
por: Kuchimanchi, Mita, et al.
Publicado: (2020) -
BIIB093 (intravenous glibenclamide) for the prevention of severe cerebral edema
por: Griepp, Daniel W., et al.
Publicado: (2021) -
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
por: Qureshi, Irfan A., et al.
Publicado: (2018) -
Poster Sessions 054-249
Publicado: (2004) -
Opération piquet PO 2000-054
por: Royer, J P
Publicado: (2000)